In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 203

In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 2030

In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 2030

The global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.

The growth of the global in vitro diagnostics market is mainly attributed to the rising prevalence of chronic diseases coupled with the increasing geriatric population, rising prevalence of acute and chronic infectious diseases, increasing funding for research activities, growing awareness regarding early disease diagnosis, growing demand for point-of-care (POC) diagnostics and rapid diagnosis, rising healthcare expenditure, and increasing funding for research activities. Moreover, the inclination of emerging economies toward personalized medicine and advancements in genomics & proteomics offer significant growth opportunities for the players operating in this market.

Based on offering, the reagents & kits segment is expected to grow with the fastest growth during the forecast period owing to its advantages as it can detect several markers simultaneously, which is useful for detecting complex diseases. Its technological superiority and the ability to facilitate chemical reactions further support the growth of this segment.

Based on the technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market. The largest share of the segment attributed to its improved specificity, cost-savings and enhanced throughput when automated, minimizing the false positive test results by targeting specific molecules, as well as improved diagnosis of infections such as orthopedic infections.

Based on diagnostic approach, the laboratory testing segment is expected to account for the largest share of the market. Lab testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. Factors such as low costs of tests, highly sensitive analyzers, more accuracy and reliability, and accessibility & availability of multiple IVD tests support the largest share of the segment.

Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the global in vitro diagnostics (IVD) market owing to the high prevalence of infectious diseases, government initiatives to promote awareness and testing, and emerging outbreaks of infectious diseases around the world.

Based on end user, the hospitals & clinics segment is expected to grow with the highest CAGR during the forecast period. Patient inflows at hospitals & clinics and subsequent increase in the volume of testing carried out in hospitals and clinics due to the outbreak of COVID-19 support the growth of this segment.

An in-depth analysis of the geographical scenario of the global in-vitro diagnostics (IVD) market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and presence of funding coupled with novel developments in diagnostic technologies support the large share of this market.

The key players operating in the global in-vitro diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).

Scope of the Report:

Global In Vitro Diagnostics Market Assessment—by Offering

Reagents & Kits
Instruments
Software & Services

Global In Vitro Diagnostics Market Assessment—by Technology

Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Hybridization
Isothermal Nucleic Acid Amplification Technology
DNA Sequencing & Next-generation Sequencing
Microarrays
Mass Spectrometry
Other Molecular Diagnostic Technologies

(Other Molecular Diagnostic Technologies majorly include electrophoresis, Ligase Chain Reaction (LCR), Northern Blot, and Southern Blot)
Point of Care (POC) Diagnostics
Lateral Flow Assays/Rapid Tests
POC Molecular Diagnostics
Other PoC Products
Immunoassay/Immunochemistry
Enzyme-linked Immunosorbent Assays (ELISA)
Enzyme-linked Immunospot Assays (ELISPOT)
Western Blotting
Radioimmunoassay
Biochemistry/Clinical Chemistry
Metabolic Panel
Electrolyte Panel
Liver Panel
Lipid Profile
Renal Profile
Thyroid Function Panel
Whole Blood Glucose Monitoring
Microbiology
Hematology
Coagulation/Hemostasis
Urinalysis
Other IVD Technologies

(Other IVD technologies comprise anatomical pathology, histochemistry, and loop-mediated amplification).

Global In Vitro Diagnostics Market Assessment—by Application

Infectious Diseases
COVID-19 Testing
Sexually Transmitted Diseases (STD) Testing
Healthcare-associated Infections (HAIs)
Hepatitis
HIV
Tropical Diseases
Respiratory Infections (Excluding Influenza)
Influenza
Other Infectious Diseases
Oncology
Diabetes
Cardiology
Nephrology
Autoimmune Disorders
Other Applications

(Other applications comprise drugs of abuse tests, coagulation tests, neonatal testing, genetic testing, and neurological disorders testing).

(Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis).

Global In Vitro Diagnostics Market Assessment—by Diagnostic Approach

Laboratory Testing
OTC/Self-testing
Point-of-Care Testing

Global In Vitro Diagnostics Market Assessment—by End User

Diagnostic Laboratories
Hospitals & Clinics
Home Healthcare
Other End Users

(Other end users comprise nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories.)

Global In vitro Diagnostics Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Saudi Arabia
Rest of Middle East
Africa
South Africa
Rest of Africa

Global In Vitro Diagnostics Market - Report Summary

Report Metrics	Details
Years Considered	2020 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	526
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Technology, Application, Diagnostic Approach, and End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa)
Key Companies Mentioned	Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy)

FAQs About the Report

What is the focus of the global in vitro diagnostics market?

The global IVD market is segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (molecular diagnostics, point-of-care (PoC), immunoassay/immunochemistry, biochemistry/clinical chemistry, whole blood glucose monitoring, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. The global IVD market studied in this report involves the value analysis of various segments and sub-segments of in vitro diagnostics at regional and country levels.

What is the value of revenue generated from selling IVD solutions across the globe?

The global IVD market is projected to reach $130.1 billion by 2030, at a CAGR of 4.6% during the forecast period.

Which offering is estimated to hold the major share of the market in 2023?

The reagents & kits segment is expected to account for the largest share of the global IVD market in 2023. Factors such as the high burden of diseases, the high adoption of rapid diagnostic test kits, and the presence of initiatives supporting early disease diagnosis support the largest share of the segment.

Which technology segment is projected to create more traction in the global IVD market?

Based on the technology, the molecular diagnostics segment is projected to create more traction.

Which application segment is projected to create more traction in the global IVD market?

Based on application, the cardiology segment is projected to register the highest growth during the forecast period due to the growing cardiovascular disease (CVD) burden and increasing research on cardiac biomarkers.

Which end-user segment is projected to create more traction in the global IVD market?

Based on end user, the hospitals & clinics segment is projected to register the highest growth during the forecast period due to increasing hospitalizations for treating diseases, the rising geriatric population, increasing healthcare access & expenditure, and the rising prevalence of healthcare-associated Infections (HAIs).

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global in vitro diagnostics market?

Rising prevalence of chronic and infectious diseases, growing awareness for early disease diagnosis, a shift in the focus from centralized to the point of care testing, and technological innovations. Further, emerging economies, the emergence of the COVID-19 pandemic, and advances in genomics and proteomics offer significant growth opportunities for the players operating in this market.

Who are the major players operating in the global IVD market?

The key players operating in the global IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).

Which regions/countries will likely offer significant growth opportunities for the vendors in this market during the analysis period?

The emerging countries from Asia and Latin America are projected to offer significant growth opportunities for the vendors in this market due to rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, growing infectious diseases, and growing accessibility to healthcare services & advanced products.